U.S. Markets closed

Artificial Intelligence (AI) in Medical Diagnostics: 2019 Patent Landscape Report

Dublin, Nov. 12, 2019 (GLOBE NEWSWIRE) -- The "Artificial Intelligence in Medical Diagnostics: Patent Landscape" report has been added to ResearchAndMarkets.com's offering.

With the development of deep learning and neural networks, artificial intelligence (AI) has gained learning capabilities. The result is that some new AIs can now recognize patterns better than human eyes. It paves the way for the emergence of a new generation of medical diagnostic devices capable of surpassing the detection skills of the best medical practitioners. Because artificial intelligence can be replicated, the expertise of these systems can become accessible to a large number of patients.

Moreover, AI has numerous and diverse applications in medical diagnostics, such as image analysis for tumor detection, video detection for gait disorders and fall prediction, biochemical tests such as for diabetes or speech analysis of emotional state and psychiatric disorders. Therefore, AI will considerably disrupt the traditional model of medical diagnosis.

More than US$1.1 billion has been invested since 2016 by companies working on the development of artificial intelligence for medical imaging. Companies such as Heartflow received US$340 million investment in the past 5 years. The main expected players in this market are the medical diagnostic systems manufacturers like. General Electric, Philips and Siemens, but also artificial intelligence-guru companies like IBM or Microsoft.

Besides these big companies, the number of Intellectual Property (IP) newcomers is important and growing. Unlike the development of new medical devices, artificial intelligence software development costs are moderate. As a result, the number of IP newcomers developing innovative software is likely to continue to rise sharply in the coming years.

Thereby, with the emergence of many new companies like Aidence, Bay Labs and doc.ai, and given the many advantages and new applications of AI for medical diagnostics, it is crucial to understand the intellectual property (IP) position and strategy of these different players. Such knowledge can help detect business risks and opportunities, anticipate emerging applications and enable strategic decisions to strengthen one's market position.

The analysis of the time evolution of patent publications shows that the development of medical diagnostic systems with built-in computer-assisted detection features is not new. The first patents related to this topic were published in the 1980s. In the 1990s Japanese medical imaging system manufacturers like Toshiba, Fujifilm, Topcon, Fujitsu, and Hitachi started to invest investigate this topic soon followed by European companies like Siemens and Philips and then by American companies like IBM, Medtronic and General Electric.

The number of patent families published each year increased progressively until 2015. Since then it has rapidly increased, and now we see the publication of more than 1,100 new patent families in 2018. This shows that AI in medical diagnostics is a very hot topic that is mobilizing great R&D efforts from different players.

The main patent assignee in the field of this study is Siemens, with more than 500 patent families. It is followed by Philips and General Electric, with more than 150 patent families each. Most main patent assignees have developed an international IP strategy. Europe-based corporations are showing the widest geographical protection for their inventions. American players mainly protect their inventions in the US and to a lesser extent in Europe and in Asian countries.

Identifying the companies that have recently emerged in the IP landscape

Among the players that have filed patents about AI in medical diagnostics, over 90 newcomers were identified. Many of these companies are startup firms currently developing their first products. These products consist of software solutions such as software for ultrasound imaging analysis, image resolution improvement or real-time brain monitoring, or medical devices capable of live analysis of biological parameters such as blood glucose monitoring apparatus, sleep monitoring sensors and ECG. Numerous IP newcomers are based in the US while some are based in Israel, in Europe or in Asia. It is possible that one of these innovative companies could become one of the next healthcare unicorns' that big corporations will be tempted to acquire.

Key Topics Covered

1. Introduction

  • AI in medical diagnostics
  • Scope of the report
  • Key features of the report
  • Objectives of the report

2. Methodology

  • Patent search, selection and analysis
  • Search strategy
  • Key patent identification
  • Terminologies for patent analysis

3. Main Assignees Mentioned

4. Executive Summary

Patent Landscape Overview

  • Global overview
  • Time evolution of patent publications
  • Countries of patent filings
  • Time evolution by country of filing
  • Main patent assignees
  • Mapping of main current IP holders
  • Patenting activity of IP leading companies
  • Time evolution for main patent assignees

IP position of the main patent assignees

  • Strength index of patent portfolios
  • IP specialization degree
  • IP blocking potential of patent applicants
  • IP leadership of patent applicants
  • Summary of applicant's patent portfolios
  • Patent assignees' main collaboration network
  • Recent collaborations

5. Key Patent Families

  • Potential future plaintiffs
  • Description of the Key Patent Families

6. Main Patent Litigations

  • Hemopet v. Nestl Purina Petcare and Hill's Pet Nutrition
  • Bessette Intellectual Property et al v. CVS Health, Walgreen and Wal Mart Stores
  • Health Discovery v. Equbits and Ciphergen Biosystems
  • Kaniadakis v. Salesforce.com et al
  • Dexcom v. Agamatrix
  • Avery et al v. Barsky
  • Healthways and Robert Bosch v. Alere
  • LD Technology LLC v. Impeto Medical SAS et al
  • Fitbit, Inc. v. AliphCom et al
  • Siemens Med. Sol. USA => Cerner Health Services v. Humedica
  • Alt v. Medtronic
  • Medical Priority Consultants et al v. VitalClick
  • Philips North America v. Fitbit and Garmin International
  • Potential future plaintiffs

7. Presentation of the IP Newcomers

  • Identification methodology
  • Introduction to the IP newcomers
  • Identification of the IP newcomers

8. Analysis By Segments

Focus on the medical examination modalities

  • Biochemical tests
  • Blood pressure
  • Cardiopulmonary sounds
  • Computed tomography (CT) scanners
  • Elastography
  • Electrocardiography
  • Electroencephalography
  • Electromyography
  • Facial analysis
  • Magnetic Resonance Imaging
  • Minimally invasive imaging
  • Movement analysis
  • Optical Coherence Tomography (OCT) imaging
  • Photoacoustic imaging
  • Positron-Emitting Tomography (PET) scanners
  • Speech analysis
  • Ultrasound imaging
  • X-rays

Focus on the clinical specialties

  • Allergies
  • Anesthesia monitoring
  • Arthropathology & Osteopathology
  • Brain injuries & Neurodegenerative diseases
  • Cardiology & Angiology
  • Diabetes
  • Gait disorder & Fall prediction
  • Hepatology
  • Infectiology
  • Irritable bowel syndrome/Inflammatory Bowel Disease
  • Ophthalmology
  • Pneumopathology
  • Pregnancy-related & Fetal conditions
  • Psychology & Psychiatry
  • Sleep disorders
  • Stomatology
  • Oncology
  • Breast cancer
  • Colorectal cancer
  • Liver cancer
  • Lung cancer
  • Prostate cancer
  • Skin cancer

9. Conclusion

Companies Mentioned

  • Abbott
  • Ajinomoto
  • Aliph
  • Alphabet
  • Bausch Health
  • Berg Pharma
  • Biomerieux
  • Boston Scientific
  • Bracco
  • Canon
  • Carestream Health
  • Caris Life Sciences
  • Carl Zeiss
  • Cognoa
  • Dexcom
  • Facense
  • Fujifilm
  • Fujitsu
  • General Electric
  • Heartflow
  • Hitachi
  • Hologic
  • IBM
  • Imaging Therapeutics
  • Johnson & Johnson
  • Konica
  • Medtronic
  • Myskin
  • Nestl
  • Olympus
  • Philips
  • Resmed
  • Roche
  • Samsung
  • Sensys Medical
  • Siemens
  • Topcon
  • Veracyte
  • Vermillion
  • Zoll Medical

For more information about this report visit https://www.researchandmarkets.com/r/tf2iao

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900